Clinical Trials Logo
  1. Home
  2. Other
  3. NCT00829608

Therapeutic Treatment With Human Papillomavirus Quadrivalent Vaccine for Recurrent Respiratory Papillomatosis

Recurrent Respiratory Papillomatosis Clinical Trial

Official title:
Investigator Initiated Study of Effects of Progression of Recurrent Respiratory Papillomatosis in Patients After They Are Given Human Papillomavirus Quadrivalent Vaccine

Clinical Trial Summary

The purpose of this study is to determine if administration of the HPV quadrivalent vaccine in patients diagnosed with RRP has a therapeutic effect on their clinical course. More specifically, does administration of the vaccine decrease the size and number of papillomas, severity of disease (i.e. hoarseness, inspiratory vs. biphasic stridor, airway obstruction) using the LCAS and time interval between required surgical debulking will be analyzed.

Clinical Trial Description

Patients who carry the diagnosis of Recurrent Respiratory Papillomatosis (RRP) will be asked to participate in the study. These patients have been followed by the faculty investigator for several years. Their disease state requires frequent interventions aimed at decreasing the severity and symptomatology of their vocal fold papillomas. Patients will be given the human papillomavirus quadrivalent vaccine and their clinical course will be followed over the next 6 months. Patients will have a laryngoscopic examination prior to treatment to establish their baseline disease state. They will have repeat laryngoscopic examinations at the time of the first, second and third vaccine injections, which will be given 1 month intervals for a total of 3 doses. They will have physical exam and laryngoscopic examinations at 1 month intervals for the first 6 months after administration of the vaccine. The severity of their clinical disease will be objectively measured using a validated scale for RRP assessment, the Laryngoscopic and Clinical Assessment Scale (LCAS). ;

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT00829608
Study type Interventional
Source University of Missouri-Columbia
Contact
Status Withdrawn
Phase Phase 0
Start date January 2009
Completion date June 2010
View Details
See also
  Status Clinical Trial Phase
Not yet recruiting NCT02854761 - Safety Study of EF-022 in Adults With Recurrent Respiratory Papillomatosis (RRP) Phase 1
Terminated NCT00747461 - Interventional Cryotherapy for the Eradication of Benign Airway Disease ("ICE the BAD") Phase 4
Completed NCT01020747 - Bevacizumab for Treatment of Recurrent Respiratory Papillomatosis (RRP) Phase 1
Completed NCT00038714 - A Trial Study of SGN-00101 in Treating Pediatric Patients With Recurrent Respiratory Papillomatosis Phase 2
Completed NCT00205374 - Use of Cidofovir for Recurrent Respiratory Papillomatosis Phase 4
Active, not recruiting NCT04724980 - Adjuvant PRGN-2012 in Adult Patients With Recurrent Respiratory Papillomatosis Phase 1/Phase 2
Not yet recruiting NCT04645602 - Lenvatinib and Pembrolizumab Combination Therapy In HPV-associated Recurrent Respiratory Papilloma Patients With Laryngeal, Tracheal, and/or Pulmonary Involvement Phase 2
Recruiting NCT01793168 - Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
Withdrawn NCT01058317 - Propranolol Administration in Pediatric Patients With Recurrent Respiratory Papillomatosis Phase 2/Phase 3
Completed NCT00550914 - Multi-Center, Randomized Trial of the Pulsed Dye Laser for JORRP N/A
Not yet recruiting NCT01995721 - 4-valent HPV Vaccine to Treat Recurrent Respiratory Papillomatosis in Children Phase 3
Completed NCT02217358 - Value of Narrow Band Imaging (NBI) Endoscopy in the Early Diagnosis of Laryngeal Cancer and Precancerous Lesions N/A
Completed NCT00571701 - Study of Celebrex (Celecoxib) in Patients With Recurrent Respiratory Papillomatosis Phase 2
Recruiting NCT02555800 - Bevacizumab Versus Cidofovir for the Treatment of Recurrent Respiratory Papillomatosis Phase 2
Completed NCT03707587 - M7824 in People With Recurrent Respiratory Papillomatosis Phase 2
Completed NCT02859454 - Avelumab for People With Recurrent Respiratory Papillomatosis Phase 2
Active, not recruiting NCT02632344 - Pembrolizumab for HPV-associated Recurrent Respiratory Papilloma Patients Phase 2
Completed NCT02592902 - Recurrent Respiratory Papillomatosis and Extraesophageal Reflux N/A
Recruiting NCT03465280 - Airway Intervention Registry (AIR): Recurrent Respiratory Papillomatosis (RRP)